Evidence supporting the use of: Omega Blend
For the health condition: Congestive Heart Failure

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Omega Blend typically refers to a supplement containing omega-3 fatty acids, such as EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), derived from fish oil or other marine sources. There is scientific interest in the role of omega-3 fatty acids in cardiovascular health, including congestive heart failure (CHF). Several clinical studies and meta-analyses have investigated whether omega-3 supplementation can benefit people with CHF. Some evidence indicates that omega-3 fatty acids may reduce inflammation, decrease arrhythmia risk, and improve endothelial function, all of which are relevant to heart failure outcomes.

The most notable study is the GISSI-HF trial (2008), a large, randomized, placebo-controlled trial that found a modest reduction in mortality and hospitalizations for heart failure patients taking 1g/day of omega-3 fatty acids compared to placebo. However, the benefits were relatively small, and subsequent research has produced mixed results. The American Heart Association has acknowledged a potential, but limited, benefit of omega-3 fatty acid supplementation in heart failure patients.

In summary, while there is scientific evidence supporting the use of omega-3 fatty acids in CHF, the effect size is modest and not universally endorsed as a core therapy. Therefore, evidence exists but is not robust or strongly conclusive, meriting a rating of 2 on the evidence scale.

More about Omega Blend
More about Congestive Heart Failure

Products containing Omega Blend

We currently have no products on Vitabase that contain this ingredient.